

Supplemental Figure 1. SickKids *P. aeruginosa* isolates (N=7 Persistent; N=7 Eradicated) were grown as biofilms for 24 hrs after which antibodies (LB control, IgG or anti-Psl 0096) and tobramycin (or LB alone) were added for the following 24 hrs before plating for colony counts. The mean colony forming unit (CFU) per well for each isolate (done in triplicate) was calculated and the log transformed ($\log_{10}$) mean of all isolates was plotted with standard error of the mean (SEM). Comparisons with and without tobramycin treatment were performed for each condition using non-parametric Mann-Whitney test ***$p<0.001$, **$p<0.01$

Strain	E/P	pslA	pslB	pslC	pslD	pslE	pslF	pslG	pslH	pslI	pslJ	pslK	pslL	pslM	pslN	pslO
263	E	0	1	1	0	0	2	0	1	1	0	3	2	1	1	0
288	E	0	1	1	0	0	2	0	1	1	1	1	1	2	1	0
325	E	0	2	2	0	1	1	0	3	2	0	2	0	1	0	1
549	E	0	0	1	0	0	2	0	1	1	1	1	1	1	1	0
558	E	0	0	1	0	0	2	0	1	1	1	1	1	1	1	0
404	E	0	2	2	0	1	1	0	3	2	0	2	0	1	0	1
50	E	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0
375	P	0	1	3	0	1	1	1	2	3	0	1	2	2	0	1
551	P	0	0	1	0	0	2	0	1	1	1	1	1	1	1	0
580	P	0	1	1	0	0	2	0	1	1	0	3	2	1	1	0
380	P	0	1	3	0	1	1	0	1	1	0	1	1	2	0	3
342	P	0	0	1	0	0	2	0	1	1	1	1	1	1	1	0
505	P	0	1	2	0	0	2	0	2	1	0	0	1	2	0	1
565	P	1	0	2	0	1	1	1	1	1	0	1	0	2	0	1
	Ttest	0.337	0.484	0.165	N/A	0.611	0.698	0.147	0.765	0.718	0.611	0.580	0.290	0.109	0.626	0.223

Supplemental Figure 2. The number of non-synonymous mutations in each Psl gene was counted for each of the 14 strains. T-test was used to determine whether there was a significant difference in the number of mutations between all 14 of the strains for each Psl gene as well as when all the Psl genes were considered together.



Supplemental Figure 3. SickKids *P. aeruginosa* isolates (N=21 Persistent; N=25 Eradicated) were grown as biofilms for 24 h then separated by centrifugation into supernatant and cellular fractions. Samples were then analyzed by western blot analysis using an anti-CdrA antibody. PAO1 was used as a positive control and the CdrA deletion strain (PAO1*ΔcdrA*) was used as a negative control. All blots derive from the same experiment and were processed in parallel.

Supplementary Figure 4

Pa342 (Persistent) Trial1



Pa342 (Persistent) Trial2



Pa342 (Persistent) Trial3



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa375 (Persistent) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa375 (Persistent) Trial2



Pa375 (Persistent) Trial3



Pa380 (Persistent) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa380 (Persistent) Trial2



Pa380 (Persistent) Trial3



Pa565 (Persistent) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa565 (Persistent) Trial2



Pa565 (Persistent) Trial3



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa580 (Persistent) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa580 (Persistent) Trial2



Pa580 (Persistent) Trial3



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa505 (Persistent) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa505 (Persistent) Trial2



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa505 (Persistent) Trial3



Pa551 (Persistent) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa551 (Persistent) Trial2



Pa551 (Persistent) Trial3



Pa549 (Eradicated) Trial1



Pa549 (Eradicated) Trial2



Pa549 (Eradicated) Trial3



Pa404 (Eradicated) Trial1



Pa404 (Eradicated) Trial2



Pa404 (Eradicated) Trial3



Pa288 (Eradicated) Trial1



Pa288 (Eradicated) Trial2



Pa288 (Eradicated) Trial3



Pa325 (Eradicated) Trial1



Pa325 (Eradicated) Trial2



Pa325 (Eradicated) Trial3



Pa263 (Eradicated) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa263 (Eradicated) Trial2





Pa263 (Eradicated) Trial3



Pa50 (Eradicated) Trial1



Pa50 (Eradicated) Trial2



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa50 (Eradicated) Trial3



Pa558 (Eradicated) Trial1



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa558 (Eradicated) Trial2



IgG

Psl0096

Control

IgG + Tobra

Psl0096 + Tobra

Control + Tobra

Pa558 (Eradicated) Trial3